Andrew Moreno

DocwireNews

A phase II non-randomized clinical trial was conducted to evaluate the interleukin (IL)-1&beta; inhibitor canakinumab for previously-treated myelodysplastic syndromes (MDS). Its findings were published in Nature Communications.The trial investigators concluded that this agent was safe overall for use in this setting and &ldquo;pharmacologically targeting the IL-1&beta; pathway represents a promising therapeutic strategy for improving hematologic parameters and reducing inflammatory cytokine levels in patients with early-stage disease.&rdquo; However, patients with high genetic complexity were seen to have greater resistance to this agent.The cohort in this open-label, single-arm trial included 25 patients, had a median age of 74 years, and was 60% male. The patients had a median of two prior lines of therapy and in 80% prior hypomethylating agents were unsuccessful. 80% of the cohort was transfusion-dependent and 40% had SF3B1 mutations.The trial began with an exploratory dose-finding run-in phase after which enrolled patients received 300&thinsp;mg of subcutaneous canakinumab on the first day of a four-week cycle. The trial cohort had a median follow-up of 24.9 months.Safety results were evaluated in the entire cohort. No patients discontinued therapy, reduced dose, or were removed from the study due to effects from the agent. Neutropenia was the most common treatment-emergent adverse event (TEAE) and cytopenia was the most common TEAE of grade 3 or worse severity. There was one mortality in the cohort due to sepsis determined to be unrelated to treatment.The median overall survival in the cohort was 17.3 months, progression-free survival was 17.3 months, and leukemia-free survival was 16.3 months. Response was evaluable in 23 patients and their overall response rate was 17.4%. Four patients responded to treatment, three of whom achieved erythroid hematological improvement and one platelet hematological improvement. There were three patients who achieved transfusion independence and they had a median duration of response of 8.53 months.The investigators noted that the patients in the cohort with SF3B1 mutations did not respond to canakinumab. Moreover, &ldquo;[a]ll patients whose disease responded to canakinumab belonged to the lower-risk group by [molecular International Prognostic Scoring System], whereas all patients whose disease progressed during treatment were in the higher-risk group.&rdquo;ReferenceRodriguez-Sevilla JJ, Adema V, Chien KS, et al. The IL-1&beta; inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial. Nat Commun. 2024;15(1):9840. doi:10.1038/s41467-024-54290-2

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

Strong Safety, Nuanced Efficacy Results for Canakinumab in Previously-Treated MDS

Phase II trial results suggest limits to the IL-1β inhibitor's efficacy by patient genetic complexity and SF3B1 mutation.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe